Trial Profile

DIVERGE-II

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Jan 2010

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Umirolimus (Primary)
Indications Coronary artery disease; Coronary artery restenosis
Focus Registrational; Therapeutic Use
Acronyms DIVERGE-II
Sponsors Devax

Most Recent Events

08 Jun 2009 New trial record.
30 May 2009 The U.S. Food and Drug Administration has conditionally approved an Investigational Device Exemption the AXXESS Biolimus A9-eluting stent, allowing the company to initiate this pivotal trial in the USA; as reported by Devax in a media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com